NCL Protein, Human (HEK293, Fc)

Nucleolar protein (NCL) is the major nucleolar protein in actively growing eukaryotic cells and is associated with intranucleolar chromatin and preribosomal granules. It induces chromatin decondensation by binding to histone H1 and plays a role in pre-rRNA transcription, ribosome assembly, and potential transcription elongation. NCL Protein, Human (HEK293, Fc) is the recombinant human-derived NCL protein, expressed by HEK293, with C-hFc labeled tag.

Nucleolin (NCL) serves as the major nucleolar protein in actively growing eukaryotic cells, associating with intranucleolar chromatin and pre-ribosomal particles. Its involvement in inducing chromatin decondensation is facilitated by binding to histone H1. Nucleolin is implicated in pre-rRNA transcription, ribosome assembly, and potentially plays a role in transcriptional elongation. It exhibits a higher affinity for RNA oligonucleotides containing 5'-UUAGGG-3' repeats compared to telomeric single-stranded DNA with 5'-TTAGGG-3' repeats. Additionally, NCL is identified in an IGF2BP1-dependent mRNP granule complex. It is part of the SWAP complex and a larger complex involving HTATSF1, CDK9, CCNT1, RNA polymerase II, SUPT5H, and Nucleolin. NCL engages in diverse interactions with proteins such as AICDA, APTX, C1QBP, ERBB4, FMR1, GZF1, NSUN2, NVL, SETX, TERT, WDR46, ZFP36, LRRC34, RRP1B, HNRNPU, RIOK1, ZBTB7B, MDK, and HDGF, highlighting its multifaceted roles in various cellular processes.

Human

HEK293

C-hFc

P19338 (V2-E710)

4691

Full Length of Mature Protein

VKLAKAGKNQGDPKKMAPPPKEVEEDSEDEEMSEDEEDDSSGEEVVIPQKKGKKAAATSAKKVVVSPTKKVAVATPAKKAAVTPGKKAAATPAKKTVTPAKAVTTPGKKGATPGKALVATPGKKGAAIPAKGAKNGKNAKKEDSDEEEDDDSEEDEEDDEDEDEDEDEIEPAAMKAAAAAPASEDEDDEDDEDDEDDDDDEEDDSEEEAMETTPAKGKKAAKVVPVKAKNVAEDEDEEEDDEDEDDDDDEDDEDDDDEDDEEEEEEEEEEPVKEAPGKRKKEMAKQKAAPEAKKQKVEGTEPTTAFNLFVGNLNFNKSAPELKTGISDVFAKNDLAVVDVRIGMTRKFGYVDFESAEDLEKALELTGLKVFGNEIKLEKPKGKDSKKERDARTLLAKNLPYKVTQDELKEVFEDAAEIRLVSKDGKSKGIAYIEFKTEADAEKTFEEKQGTEIDGRSISLYYTGEKGQNQDYRGGKNSTWSGESKTLVLSNLSYSATEETLQEVFEKATFIKVPQNQNGKSKGYAFIEFASFEDAKEALNSCNKREIEGRAIRLELQGPRGSPNARSQPSKTLFVKGLSEDTTEETLKESFDGSVRARIVTDRETGSSKGFGFVDFNSEEDAKAAKEAMEDGEIDGNKVTLDWAKPKGEGGFGGRGGGRGGFGGRGGGRGGRGGFGGRGRGGFGGRGGFRGGRGGGGDHKPQGKKTKFE

Approximately 130-150 kDa,based on SDS-PAGE under reducing conditions,due to the glycosylation.

Greater than 90% as determined by reducing SDS-PAGE.

<1 EU/μg, determined by LAL method.